Using PET/CT imaging to evaluate estrogen receptors in breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy of 18F-Fluoroestradiol (18F-FES) PET/CT imaging in evaluating estrogen receptor (ER) expression levels in patients with primary and metastatic breast cancer. The study focuses on understanding the heterogeneity of estrogen receptors and their role in treatment response and pharmacokinetics of estrogen receptor-targeted therapies. By utilizing a highly sensitive and specific imaging tracer, the study seeks to provide insights into the biological characteristics of breast cancer and improve treatment strategies for patients. Participants will undergo PET/CT scans to measure ER levels, contributing to a better understanding of breast cancer pathology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* More than 18 years old
* Patients with pathologically confirmed breast cancer
* Sign the informed consent form

Exclusion Criteria:

* Pregnant women
* Severe underlying diseases that cannot cooperate with PET examination

Where it's running

• TongjiHospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Zhu Xiaohua, Dr — Tongji Hospital
• Study coordinator: Zhu Xiaohua, Dr
• Email: evazhu@vip.sina.com
• Phone: 13971513770

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC

  This imaging study tests how well the imaging agent works in people with metastatic urothelial cancer, various breast cancers, or NSCLC.

  Recruiting at 4 sites Early Phase 1 RayzeBio, Inc. · St Leonards, New South Wales and 5 other locations · NCT07671092

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

• Boosting immunotherapy response in high-risk triple-negative breast cancer with CSF-1R blockade and radiation

  This will try pembrolizumab with axatilimab and radiation before surgery to see if it increases complete tumor disappearance in adults with high-risk triple-negative breast cancer.

  Recruiting Phase 2 Cedars-Sinai Medical Center · Los Angeles, California · NCT05491226

• Examining the immune environment in different types of breast cancer

  This study looks at tissue samples from women with different types of breast cancer to see how the immune environment affects treatment responses.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05396612

• Combining radiation therapy with pembrolizumab and olaparib for certain breast cancers

  This study tests if adding pembrolizumab, with or without olaparib, to standard radiation therapy can help women with advanced breast cancer feel better compared to just radiation therapy alone.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04683679

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.